---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence. Covers Himalayas-1 and ORIC-944-01. 121 evidence topics quoted from 22 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 Himalayas-1

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Primary objective: radiographic progression-free survival superiority

> “The primary objective of this study is to demonstrate superiority in radiographic progression free survival (rPFS) of the investigational arm of rinzimetostat + darolutamide combination versus physician's choice of control: ARPI (darolutamide or enzalutamide) or docetaxel.”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.1-2"></a>

###### Comparison evaluated in the trial

> “Himalayas-1 is evaluating whether rinzimetostat plus darolutamide improves outcomes compared with physician’s choice of an ARPI or docetaxel in patients with mCRPC previously treated with abiraterone”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Registry status and dates

| Study characteristic | Quoted record |
| --- | --- |
| Overall status | “Recruiting” |
| Study start (actual) | “2026-08-03” |
| Primary completion (estimated) | “2028-03” |
| Study completion (estimated) | “2030-09” |
| First posted | “2026-07-23” |

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.2-2"></a>

###### Planned sites and countries

> “Himalayas-1 is a global study planned across approximately 250 study sites in 25 countries”
> “Study initiated in July 2026”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-3.1.1.2-3"></a>

###### Announcement of trial initiation

> “today announced the initiation of the Himalayas-1 global Phase 3 registrational trial in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-3.1.1.2-4"></a>

###### Anticipated primary endpoint readout relative to cash runway

> “Cash and investments of approximately $388 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout from first Phase 3 trial for rinzimetostat”

Source: [ORIC Pharmaceuticals second quarter results (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-second-quarter-2026-financial-results-and-operational-updates/)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Randomized phase 3 design with physician's choice of control

| Study characteristic | Quoted record |
| --- | --- |
| Design | “Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Protocol number | “ORIC-944-05” |
| EU trial number | “2026-525340-15-00” |

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.3-2"></a>

###### Randomization and stratification

| Design element | Quoted record |
| --- | --- |
| Randomization | “Patients will be randomized 1:1 to receive rinzimetostat 400 mg QD plus darolutamide 600 mg BID, or prespecified physician’s choice of control (ARPI or docetaxel)” |
| Second randomization within the ARPI control | “If the prespecified control is ARPI, patients will undergo a second 1:1 randomization to darolutamide 600 mg BID or enzalutamide 160 mg QD” |
| Stratification factors | “Randomization will be stratified by prior docetaxel use in the metastatic castration-sensitive prostate cancer (mCSPC) setting, prespecified control category (ARPI versus docetaxel), and presence of hepatic metastases” |

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-3.1.1.3-3"></a>

###### Protocol finalized after end-of-phase 1 interactions with regulators

> “Following End-of-Phase 1 interactions with the FDA and other global health authorities, ORIC finalized the trial protocol and has initiated the Himalayas-1 global Phase 3 registrational trial.”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-3.1.1.3-4"></a>

###### Sponsorship and darolutamide supply agreement

> “On July 7, 2026, the Company entered into a clinical trial collaboration and supply agreement with Bayer Consumer Care AG (Bayer)”
> “The Company will conduct and sponsor the Himalayas-1 trial and maintain full economic ownership and control of rinzimetostat.”

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Key inclusion criteria

> “Male patients aged ≥18 years”
> “Histologically or cytologically confirmed prostate adenocarcinoma without small cell features”
> “Progressive disease in the setting of surgical or medical castration, with evidence of disease progression as per PCWG3 on treatment with abiraterone ≥12 weeks in the mCSPC setting or first-line mCRPC setting”
> “Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan”
> “ECOG PS of 0 or 1”
> “Adequate organ function”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-3.1.1.4-2"></a>

###### Key exclusion criteria

> “Prior systemic anticancer therapy, beyond protocol-permitted abiraterone-based treatment and docetaxel in the mCSPC setting”
> “Radiotherapy within 2 weeks before randomization”
> “Known or suspected brain metastases or active leptomeningeal disease”
> “Clinically significant cardiovascular disease”
> “Active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-3.1.1.4-3"></a>

###### Excluded and permitted prior therapies in the registry record

> “Prior treatment for prostate cancer at any stage with cytotoxic chemotherapy, radioligand therapy (ie, 177Lu -PSMA-617, radium-223), ARPIs including apalutamide, darolutamide, and enzalutamide, PARP monotherapy or other systemic anticancer treatment (approved drugs or experimental compounds such as, antibody therapy, immunotherapy, gene or cell therapy, angiogenesis inhibitors, CDK4/6 inhibitors, PRC2 inhibitors) with the following exceptions:”
> “Treatment with first-generation antiandrogen agents (eg, bicalutamide, flutamide, nilutamide), but must be discontinued prior to the first dose of study medication”
> “Docetaxel treatment is allowed for mCSPC, as long as no signs of failure or disease progression occurred during treatment or within 3 months of treatment completion”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Investigational and control regimens

| Study drug and arm | Quoted dose and schedule |
| --- | --- |
| Rinzimetostat (investigational arm) | “400 mg once daily (QD)” |
| Darolutamide (investigational arm and physician's choice) | “600 mg twice daily (BID)” |
| Enzalutamide (physician's choice) | “160 mg once daily (QD)” |
| Docetaxel (physician's choice) | “75 mg/m2 intravenously (IV) every 21 days for up to 10 cycles” |

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.5-2"></a>

###### Rinzimetostat dosing with or without food

> “randomized 1:1 to receive the RP3D of 400 mg once daily rinzimetostat (with or without food) in combination with darolutamide versus physician’s choice of an androgen receptor (AR) inhibitor or docetaxel”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-3.1.1.5-3"></a>

###### Basis for the rinzimetostat dose

> “Phase 1b dose-optimization data supported selection of rinzimetostat 400 mg once daily (QD) in combination with darolutamide 600 mg twice daily (BID) for evaluation in Himalayas-1”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

> “The analysis demonstrated that 400 mg and 600 mg once daily provided comparable efficacy.”
> “Based on these findings 400 mg once daily in combination with darolutamide has been selected as the RP3D for rinzimetostat.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Radiographic Progression-free Survival by Blinded Independent Central Review as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Trial definition of radiographic progression-free survival

> “Radiographic Progression Free Survival is defined as the time from the date of randomization to first evidence of radiographic progression as assessed in soft tissue by RECIST 1.1 or in bone per PCWG3 guideline by BICR, or death, whichever occurs first”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.6.1-2"></a>

###### Assessment of the primary endpoint

> “BICR per RECIST v1.1 for soft-tissue disease or per PCWG3 criteria for bone disease, or death from any cause, whichever occurs first”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-3.1.1.6.1-3"></a>

###### Key secondary endpoint: overall survival

> “OS is defined as time from date of randomization to date of death due to any cause”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.6.1-4"></a>

###### Other secondary efficacy, safety, and pharmacokinetic endpoints

| Endpoint | Quoted registry definition |
| --- | --- |
| Objective response rate | “ORR is defined as proportion of patients with measurable soft tissue disease at baseline who have a confirmed objective response of complete response (CR) or partial response (PR)” |
| Duration of response | “DOR is defined as time of first response to first documentation of radiographic progression or death, whichever occurs first” |
| Prostate-specific antigen response | “Defined as the proportion of patients with a confirmed ≥50% and ≥90% decline in PSA from baseline as per the PCWG3 criteria, along with the maximum decline in PSA occurring at any point on study” |
| Time to PSA progression | “Measured from the start of treatment until criteria for PSA progression are met as per PCWG3” |
| Time to first symptomatic skeletal event | “Time from randomization to first symptomatic skeletal event (symptomatic bone fractures, spinal cord compression, surgery or radiation to the bone whichever is first)” |
| Adverse events | “Type, incidence, relationship to study treatments, severity, and seriousness of AEs” |
| Pharmacokinetics | “Rinzimetostat characterized by predose and postdose plasma concentrations at selected time points” |

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.6.1-5"></a>

###### Patient-reported outcome endpoints

| Domain | Quoted registry outcome measure |
| --- | --- |
| Pain | “Change from baseline in patient reported pain symptoms per Brief Pain Inventory-Short Form (BPI-SF)” |
| Health-related quality of life | “Change from baseline in health-related quality of life (HRQoL) per Functional Assessment of Cancer Therapy - Prostate (FACT-P)” |
| Health status | “Change from baseline in patient reported health status per European Quality of Life 5-Dimension 5 Level (EQ-5D-5L)” |
| Symptomatic toxicity | “Symptomatic toxicity as measured by items from the Patient-Reported Outcome CTCAE (PRO-CTCAE)” |
| Pain progression | “Time to confirmatory deterioration in patient-reported pain symptoms per BPI-SF Item 3” |
| Quality-of-life deterioration | “Time to definitive deterioration in patient-reported health related quality of life (HRQoL) per FACT-P” |

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.6.1-6"></a>

###### Consensus definition of radiographic progression-free survival

> “Radiographic progression-free survival (rPFS) is the time interval from random assignment to the date when the first site of disease is found to progress (using a manifestation-specific definition of progression), or death, whichever occurs first.”
> “Of particular note is the use of the 2+2 rule to distinguish flare from true progression in patients with osseous disease at baseline”

Source: [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/)

<a id="topic-3.1.1.6.1-7"></a>

###### Consensus position on the association with overall survival

> “The association between rPFS and overall survival is still being investigated, but an association was demonstrated in at least one of these trials.”
> “The suitability of efficacy end points to demonstrate clinical benefit is context dependent, and consultation with regulatory authorities is strongly recommended when selecting and defining end points for a trial intended to support drug approval.”

Source: [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/)

<a id="topic-3.1.1.6.1-8"></a>

###### Patient-level correlation with overall survival in chemotherapy-naive mCRPC treated with abiraterone

> “Spearman's correlation coefficient between rPFS and OS was 0.72.”
> “These data make no surrogate claims of rPFS and do not provide support for the use of rPFS to serve as a substitute for OS at this juncture.”

Source: [Morris et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4881370/)

<a id="topic-3.1.1.6.1-9"></a>

###### Patient-level correlation with overall survival in chemotherapy-naive mCRPC treated with enzalutamide

> “Spearman ρ was 0.72 (95% CI, 0.67-0.76) among all patients, 0.89 (95% CI, 0.86-0.92) among enzalutamide-treated patients, and 0.53 (95% CI, 0.43-0.61) among placebo-treated patients.”
> “In our analysis, the lower correlation between rPFS and OS seen with placebo-treated patients than seen with enzalutamide-treated patients could be partly related to postprotocol exposure to life-prolonging therapy.”

Source: [Rathkopf et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5885186/)

<a id="topic-3.1.1.6.1-10"></a>

###### Patient-level correlation with overall survival after prior androgen receptor pathway inhibitor and taxane

> “In the overall population, rPFS correlated strongly with OS (rho ≥ 0.7).”
> “Correlations between rPFS or OS and time to SSE without death were weak or mild.”

Source: [Morris et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11851234/)

<a id="topic-3.1.1.6.1-11"></a>

###### Trial-level surrogacy in first-line mCRPC naive to androgen receptor pathway inhibitors

> “Eleven RCTs were identified.”
> “Using the methodology recommended by the German health authority IQWiG, this study supports rPFS as a valid intermediate endpoint for OS in first-line ARPi naïve mCRPC.”

Source: [Castro et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12832950/)

<a id="topic-3.1.1.6.1-12"></a>

###### Trial-level surrogacy across advanced prostate cancer

> “A total of 143 randomized trials (n=75,601 patients) were included.”
> “radiographic PFS [n=52,548], 0.50 [95% CI, 0.35 to 0.63]”
> “Our aggregate screening method for surrogate end points in advanced prostate cancer showed that commonly used clinical end points are not clear valid surrogate end points for OS.”

Source: [Gharzai et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38320030/)

<a id="topic-3.1.1.6.1-13"></a>

###### Clinical progression without radiographic progression

> “Of 736 patients with disease progression, 280 (38%) had UCP-only and 124 (17%) had UCP plus RAD.”
> “Including UCP events lowered estimates of treatment benefit—median crPFS was 13.3 months (95% CI 11.1 to 13.8) versus median rPFS of 16.5 months (95% CI 13.8 to 16.8) in AAP group.”

Source: [Rao et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7662417/)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned randomized participants

> “Approximately 600 patients will be randomized 1:1 to rinzimetostat plus darolutamide versus physician’s choice of ARPI (1:1 to darolutamide or enzalutamide) or docetaxel”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned enrollment by sites and countries

> “The Himalayas-1 trial is expected to enroll approximately 600 patients from over 250 sites in 25 countries”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Planned primary analysis of radiographic progression-free survival

> “rPFS will be compared between treatment groups using a stratified log-rank test based on the three randomization stratification factors.”
> “The hazard ratio and corresponding 95% confidence interval will be estimated using a stratified Cox regression model, and Kaplan-Meier methods will be used to summarize rPFS”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="topic-3.1.1.7.2-2"></a>

###### Hierarchical testing of overall survival

> “OS will be formally tested only if the primary rPFS analysis is statistically significant and will be analyzed using corresponding stratified log-rank, Cox regression, and Kaplan-Meier methods”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: design and data limitations

- No Himalayas-1 results are available. The registry lists the trial as “Recruiting”, with an actual start of 2026-08-03 and estimated primary completion in 2028-03; the design information comes from the registry record, ORIC press releases and filings, and a trial-in-progress poster hosted on the ORIC website.
- The trial is open label, with no masking (“None (Open Label)”). The primary endpoint, rPFS, is assessed by blinded independent central review per RECIST 1.1 for soft tissue and PCWG3 for bone.
- The control is a prespecified physician’s choice of an ARPI or docetaxel. Participants assigned to the ARPI control undergo a second 1:1 randomization to darolutamide or enzalutamide, so darolutamide is given in the investigational arm and in part of the control arm; randomization is stratified by control category, prior docetaxel in mCSPC, and hepatic metastases.
- Overall survival is a key secondary endpoint, formally tested only if the primary rPFS analysis is statistically significant. A consensus statement describes the association between rPFS and overall survival as “still being investigated”; a trial-level analysis of 143 randomized trials in advanced prostate cancer concluded that commonly used clinical end points “are not clear valid surrogate end points for OS”, while an analysis of 11 randomized trials supported rPFS as a valid intermediate endpoint in first-line ARPI-naive mCRPC, a population that differs from the post-abiraterone population of Himalayas-1.
- Eligibility limits the population to participants with ECOG performance status 0 or 1 and adequate organ function, and excludes brain metastases, clinically significant cardiovascular disease, active inflammatory gastrointestinal disease, and prior treatment with ARPIs other than abiraterone, chemotherapy other than docetaxel for mCSPC, radioligand therapy, PARP monotherapy, or PRC2 inhibitors.
- The 400 mg dose was selected from phase 1b dose-optimization data in 18 participants at 400 mg and 15 at 600 mg. ORIC conducts and sponsors the trial, and Bayer supplies darolutamide.

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248); [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf); [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/); [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/); [Gharzai et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38320030/); [Castro et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12832950/); [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/); [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm)

<a id="topic-3.1.1.9-2"></a>

###### Open-label design

> “A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination With Darolutamide Compared With ARPI or Docetaxel in Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (Himalayas-1)”
> “None (Open Label)”

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-3.1.1.9-3"></a>

###### Prespecified physician's choice of control

> “Himalayas-1 (NCT07723248) is a global, randomized, open-label Phase 3 study evaluating rinzimetostat plus darolutamide versus a prespecified physician’s choice of ARPI or docetaxel control in approximately 600 patients with mCRPC previously treated with abiraterone”

Source: [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)

<a id="heading-3.1.2"></a>

#### 3.1.2 ORIC-944-01

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Study purpose: single agent and combination with androgen receptor pathway inhibitors

> “The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.”
> “Part III of the protocol (dose optimization) will explore two potential dose levels of ORIC-944 selected from Part II in combination with ARPIs to select the final RP2D for each combination across two separate patient populations.”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-3.1.2.1-2"></a>

###### Single-agent dose escalation: objective

> “Phase 1b designed to confirm ORIC-944 differentiated single agent profile and to position ORIC-944 as a potential best-in-class PRC2 inhibitor for combination development in prostate cancer”

Source: [ORIC Pharmaceuticals January presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525005028/d908680dex991.htm)

<a id="topic-3.1.2.1-3"></a>

###### Combination dose optimization: objective of selecting the recommended phase 3 dose

> “The primary objective of the trial is to determine the RP3D, and additional objectives include safety, tolerability, pharmacokinetics, and preliminary clinical activity.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-3.1.2.1-4"></a>

###### Food-effect cohort: objective

> “Rinzimetostat is being studied in a food effect cohort to potentially enable dosing under fed conditions, consistent with darolutamide dosing”
> “ORIC is currently evaluating the impact of food for rinzimetostat plus darolutamide on PK, PD, safety and efficacy”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Registry dates

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2022-06-01” |
| Primary completion (estimated) | “2027-06” |
| Study completion (estimated) | “2028-04” |

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-3.1.2.2-2"></a>

###### Study sites in the United States, Australia, Spain, and the United Kingdom

> “Memorial Sloane Kettering Cancer Center”
> “Huntsman Cancer Institute, University of Utah”
> “University of Washington, Fred Hutchinson Cancer Center”
> “Sydney Adventist Health”
> “Vall d'Hebron Institute of Oncology”
> “Royal Marsden NHS Foundation Trust”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-3.1.2.2-3"></a>

###### Investigational new drug application and start of combination dosing

> “We filed and cleared an IND with the FDA for rinzimetostat in the fourth quarter of 2021.”
> “In mid-2024, we initiated dosing of rinzimetostat in combination with 240 mg QD apalutamide as well as in combination with 600 mg BID darolutamide, as part of the ongoing Phase 1b trial in patients with mCRPC.”

Source: [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

<a id="topic-3.1.2.2-4"></a>

###### Clinical supply collaborations for the combination cohorts

> “We will continue to conduct and sponsor the ongoing Phase 1b clinical trial, and Bayer will provide darolutamide for the trial.”
> “We will continue to conduct and sponsor the ongoing Phase 1b clinical trial, and Johnson & Johnson will provide apalutamide for the trial.”

Source: [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

<a id="topic-3.1.2.2-5"></a>

###### Completion of dose exploration in November 2025

> “In November 2025, we announced the completion of the dose exploration portion of the Phase 1b trial and the selection of provisional RP2Ds of rinzimetostat for the dose optimization portion of the Phase 1b trial.”

Source: [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### First-in-human, open-label, multicenter, three-part design

> “An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer”
> “This is a first-in-human, open-label, multicenter, dose escalation study of ORIC-944 as a single agent (Part I) or in combination with an Androgen Receptor Pathway Inhibitor (ARPI) (Part II) to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combination with ARPIs in patients with metastatic prostate cancer.”
> “Interval 3+3 dose escalation design”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-3.1.2.3-2"></a>

###### Combination dose optimization cohorts by partner androgen receptor inhibitor

> “Cohort A and C: ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles in combination with apalutamide”
> “Cohort B and D: ORIC-944 dosed orally on a continuous daily dosing regimen in 28-day cycles in combination with darolutamide”
> “Combinations with abiraterone or enzalutamide may be conducted in the future”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-3.1.2.3-3"></a>

###### Combination dose exploration: November 2025 update

> “Dose exploration update (November 2025) includes 20 patients, 17 of which were previously disclosed in May 2025”

Source: [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm)

<a id="topic-3.1.2.3-4"></a>

###### Combination dose optimization: March 2026 update

> “Phase 1b, Multicenter, Open-Label Trial (in Collaboration with Bayer and Johnson & Johnson)”
> “Dose optimization data reported in post-abiraterone mCRPC, with Phase 3 trial initiation expected in 1H 2026; ORIC continuing to evaluate rinzimetostat in combination with darolutamide and apalutamide in mCRPC patients”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.3-5"></a>

###### Post-androgen receptor inhibitor and food-effect cohorts

> “Rinzimetostat 400 mg QD plus darolutamide is currently being evaluated in a food effect cohort.”
> “The company is also evaluating additional prostate cancer populations for future potential Phase 3 trials in mCRPC and mCSPC.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Inclusion criteria: disease and castration status

> “Patients with metastatic prostate cancer”
> “Must have undergone bilateral orchiectomy or be willing to continue GnRH analogue or antagonist to maintain castrate levels of testosterone”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-3.1.2.4-2"></a>

###### Inclusion criteria: prior therapy by study part

> “Part I (single agent ORIC-944 dose escalation): Any number of prior therapies are allowed, but must have progressed after at least one line of next generation ARPI (abiraterone, apalutamide, darolutamide, or enzalutamide) and must not have received more than 2 chemotherapy regimens in the mCRPC setting”
> “Part II (ARPI combination dose escalation): Must have received only 1 prior line of ARPI (abiraterone, apalutamide, darolutamide, or enzalutamide) in any setting; may have also received up to 1 prior line of chemotherapy in the mCSPC setting”
> “Cohorts A and B: received only one 1 prior line of abiraterone in any setting”
> “Cohorts C and D: received only one 1 prior line of apalutamide, darolutamide, or enzalutamide in any setting”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-3.1.2.4-3"></a>

###### Inclusion criteria: progression, measurable disease, biopsies, and performance status

> “Evidence of progressive disease by PCWG3 criteria for study entry”
> “rising PSA, defined as a minimum of 2 rising values obtained a minimum of one week apart with the latest result being at least 2.0 ng/mL (or 1.0 ng/mL if PSA rise is the only indication of progression), or”
> “confirmation of 2 new bone lesions on last systemic therapy, or”
> “soft tissue progression per RECIST 1.1”
> “Measurable and/or evaluable disease by RECIST 1.1”
> “Agreement and ability to undergo on-study punch skin biopsies and core tumor biopsies”
> “ECOG performance status of 0 or 1”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-3.1.2.4-4"></a>

###### Exclusion criteria

> “History or presence of CNS metastases, unless previously treated and stable”
> “History of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months”
> “Active symptomatic Hepatitis B or C infection; patients with well controlled disease are eligible”
> “Active gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, short gut syndrome, etc) or other malabsorption syndromes that would reasonably impact drug absorption per investigator judgement”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-3.1.2.4-5"></a>

###### Combination cohorts: key eligibility as presented by the company

> “Key Eligibility Patients with mCRPC Previously treated with an ARPI (e.g., abiraterone, enzalutamide, apalutamide, or darolutamide) May have received up to 1 line of chemotherapy”

Source: [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm)

> “Patients are eligible if they have received prior treatment with an ARPI and up to one prior chemotherapy.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Registry interventions and regimens

| Intervention | Quoted regimen |
| --- | --- |
| ORIC-944 | “Oral, once daily, continuous” |
| Apalutamide | “Oral, 240 mg once daily, continuous” |
| Darolutamide | “Oral, 600 mg twice daily, continuous” |
| Abiraterone acetate | “Oral, 1000 mg once daily, continuous” |
| Enzalutamide | “Oral, 160 mg once daily, continuous” |

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-3.1.2.5-2"></a>

###### Single-agent dose escalation: dose levels at the December 2024 cutoff

> “Dose Level (QD) 100 mg (N=3) 200 mg (N=4) 400 mg (N=3) 600 mg (N=3) 700 mg (N=3) 800 mg (N=3) 900 mg (N=6) Total (N=25)”

Source: [ORIC Pharmaceuticals January presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525005028/d908680dex991.htm)

<a id="topic-3.1.2.5-3"></a>

###### Apalutamide combination dose escalation: first two cohorts at the December 2024 cutoff

> “As of the December 10, 2024 data cut-off, the Company completed the first two ORIC-944 dose escalation cohorts (n=6 patients) for the apalutamide combination.”
> “Dose escalation for the combination of ORIC-944 with darolutamide is also ongoing with the first dose cohort completed and the second enrolling.”

Source: [ORIC Pharmaceuticals early combination data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-provides-early-phase-1b-combination-data-for-oric-944-operational-highlights-for-2024-and-anticipated-upcoming-milestones/)

<a id="topic-3.1.2.5-4"></a>

###### Combination dose exploration: dose levels at the May 2025 cutoff

> “Patients were treated once daily with 400 mg, 600 mg, or 800 mg of ORIC-944 in combination with 240 mg of apalutamide once daily or with 600 mg of darolutamide twice daily.”

Source: [ORIC Pharmaceuticals preliminary phase 1b data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-potentially-best-in-class-preliminary-efficacy-and-safety-data-from-ongoing-phase-1b-trial-of-oric-944-in-combination-with-ar-inhibitors-for-the-treatment-of-patie/)

<a id="topic-3.1.2.5-5"></a>

###### Combination dose exploration: dose levels at the September 2025 cutoff and provisional doses for dose optimization

> “Patients were treated once daily with 400 mg, 600 mg, 800 mg, or 1,200 mg of ORIC-944 in combination with 240 mg of apalutamide once daily or with 600 mg of darolutamide twice daily.”
> “400 mg and 600 mg once daily of ORIC-944 in combination with 600 mg twice daily of darolutamide; and 600 mg, 800 mg and 1,200 mg once daily of ORIC-944 in combination with 240 mg once daily of apalutamide.”

Source: [ORIC Pharmaceuticals dose exploration completion release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-completion-of-dose-exploration-portion-of-oric-944-phase-1b-clinical-trial-and-continues-to-demonstrate-potential-best-in-class-efficacy-and-safety/)

<a id="topic-3.1.2.5-6"></a>

###### Darolutamide dose optimization, 400 mg and 600 mg: regimens at the January 2026 cutoff

> “18 patients were treated with 400 mg of rinzimetostat once daily and 15 patients were treated with 600 mg of rinzimetostat once daily, both in combination with the standard dose of darolutamide at 600 mg twice daily.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-3.1.2.5-7"></a>

###### Post-androgen receptor inhibitor cohort: regimen at the March 2026 cutoff

> “Rinzimetostat 400 mg QD + Darolutamide (n=19)”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Recommended Phase 2 Dose as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Registry primary and secondary outcome measures

> “RP2D as determined by interval 3+3 dose escalation design”
> “PK of ORIC-944 single agent and in combination with an ARPI”
> “On-treatment PSA levels and change from baseline”
> “Prostate cancer working group 3 criteria (PCWG3)”

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-3.1.2.6.1-2"></a>

###### Combination dose optimization: primary, secondary, and exploratory endpoints at the March 2026 update

> “Primary endpoints: Safety and Recommended Phase 3 Dose Key secondary endpoints: rPFS, ORR, and DOR Exploratory endpoints: PSA, ctDNA, H3K27 trimethylation, PRC2 target gene expression, and genomics”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.6.1-3"></a>

###### Single-agent dose escalation: tolerability beyond the projected efficacious dose

> “ORIC-944 single agent was well-tolerated up to 900 mg QD, well beyond efficacious dose projections and maximal PD activity”

Source: [ORIC Pharmaceuticals January presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525005028/d908680dex991.htm)

<a id="topic-3.1.2.6.1-4"></a>

###### Combination dose exploration: basis for the provisional recommended phase 2 doses

> “Based on these efficacy and safety results, ORIC has selected provisional recommended Phase 2 doses (RP2Ds) of ORIC-944 to be tested in combination with the approved doses of darolutamide and apalutamide in the dose optimization portion of the Phase 1b trial”
> “Data from the dose optimization portion of the trial will inform the choice of ORIC-944 dose to advance in combination with apalutamide or with darolutamide in the first global Phase 3 registrational trial in mCRPC, which the company expects to initiate in 1H 2026.”

Source: [ORIC Pharmaceuticals dose exploration completion release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-completion-of-dose-exploration-portion-of-oric-944-phase-1b-clinical-trial-and-continues-to-demonstrate-potential-best-in-class-efficacy-and-safety/)

<a id="topic-3.1.2.6.1-5"></a>

###### Darolutamide dose optimization: recommended phase 3 dose selected by exposure-response analysis under Project Optimus

> “To support the selection of the recommended Phase 3 dose in accordance with the FDA's Project Optimus initiative, the company conducted a comprehensive exposure-response (E-R) analysis in over 100 patients across both the single-agent and combination data evaluating the relationship between rinzimetostat drug exposure versus efficacy and safety outcomes.”
> “The analysis demonstrated that 400 mg and 600 mg once daily provided comparable efficacy. In contrast, the E-R analysis identified statistically significant relationships between higher drug exposure and toxicities as well as increased rates of treatment modifications, clearly favoring the 400 mg dose on the basis of safety.”
> “Based on these findings 400 mg once daily in combination with darolutamide has been selected as the RP3D for rinzimetostat.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-3.1.2.6.1-6"></a>

###### Exposure-response analysis: objective, methods, and correlations at the January 2026 cutoff

> “Objective: Select the RP3D between 400 mg QD vs 600 mg QD by evaluating relationships between exposure of rinzimetostat to various safety / tolerability and efficacy measures”
> “Methods: Exposure-response analyses were conducted using data across the entire rinzimetostat clinical dataset (single-agent and combination, n=113 patients)”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

| Measure | Statistically significant correlation to exposure |
| --- | --- |
| Adverse events (G2+, G3+, SAEs) | “Significant correlation” |
| Specific adverse events (GI, heme) | “Significant correlation” |
| Treatment modifications | “Significant correlation” |
| Radiographic PFS | “No correlation” |
| PSA reduction | “No correlation” |
| ctDNA reduction | “No correlation” |
| Changes in H3K27me3 trimethylation | “No correlation” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “Analyses demonstrated no exposure-efficacy correlation; however, 400 mg QD was associated with lower toxicity and fewer dose modifications, supporting its selection as the RP3D in combination with darolutamide”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.6.1-7"></a>

###### End-of-phase 1 interactions with regulators

> “Finalized the trial protocol and initiated the Himalayas-1 global Phase 3 registrational trial following End-of-Phase 1 interactions with the FDA and other global health authorities.”

Source: [ORIC Pharmaceuticals second quarter results (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-second-quarter-2026-financial-results-and-operational-updates/)

<a id="topic-3.1.2.6.1-8"></a>

###### PSA50 and PSA90 response: confirmation

> “90 – confirmed PSA90 response; u50 – unconfirmed PSA50 response”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “59% of patients (10/17) achieved a PSA50 response and nearly all patients with a PSA50 response were confirmed one month later”

Source: [ORIC Pharmaceuticals preliminary phase 1b data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-potentially-best-in-class-preliminary-efficacy-and-safety-data-from-ongoing-phase-1b-trial-of-oric-944-in-combination-with-ar-inhibitors-for-the-treatment-of-patie/)

<a id="topic-3.1.2.6.1-9"></a>

###### Circulating tumor DNA response and clearance: definitions

> “Molecular response (MR) defined as decrease in ctDNA fraction relative to baseline. Best percent change in ctDNA fraction from baseline assessed at the start of cycle 2, cycle 7, or end of treatment.”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “D: Detected ctDNA ≥0.5% ND: Non-detected ctDNA <0.5%”
> “ctDNA response was assessed at C2D1 in ORIC Phase 1b, at C3D1 in IMbassador250 and at C4D1 in FIRSTANA/PROSELICA.”

Source: [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm)

<a id="topic-3.1.2.6.1-10"></a>

###### Circulating tumor DNA: stated prognostic rationale

> “ctDNA serves as a useful biomarker to predict the duration of treatment benefit and survival in prostate cancer. Detectable ctDNA at baseline is associated with poor prognosis, and non-detectable ctDNA at baseline or upon treatment is associated with longer progression-free survival and overall survival.”

Source: [ORIC Pharmaceuticals dose exploration completion release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-completion-of-dose-exploration-portion-of-oric-944-phase-1b-clinical-trial-and-continues-to-demonstrate-potential-best-in-class-efficacy-and-safety/)

<a id="topic-3.1.2.6.1-11"></a>

###### Landmark radiographic progression-free survival: stated rationale

> “PRC2 inhibitors in combination with an AR inhibitor have demonstrated much longer rPFS (key regulatory primary endpoint) than what has been reported with other approved and emerging therapies”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned enrollment

| Field | Quoted record |
| --- | --- |
| Enrollment (estimated) | “275” |

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)

<a id="topic-3.1.2.7.1-2"></a>

###### Single-agent dose escalation: participants at the December 2024 cutoff

> “Treatment-Related Adverse Events Occurring in ≥10% of Patients in Single Agent Dose Escalation”
> “Total (N=25)”

Source: [ORIC Pharmaceuticals January presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525005028/d908680dex991.htm)

<a id="topic-3.1.2.7.1-3"></a>

###### Combination dose exploration: participants at the May 2025 cutoff

> “Data include 17 patients with mCRPC previously treated with a median of three lines of prior therapy, including abiraterone, up to one prior line of chemotherapy, and a variety of other approved and investigational treatment regimens.”

Source: [ORIC Pharmaceuticals preliminary phase 1b data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-potentially-best-in-class-preliminary-efficacy-and-safety-data-from-ongoing-phase-1b-trial-of-oric-944-in-combination-with-ar-inhibitors-for-the-treatment-of-patie/)

<a id="topic-3.1.2.7.1-4"></a>

###### Combination dose exploration: participants at the September 2025 cutoff

> “PSA data for 20 patients with mCRPC includes 17 patients previously reported in May 2025. Circulating tumor DNA (ctDNA) was assessed for 17 patients with mCRPC who had available ctDNA samples and evidence of ctDNA at baseline prior to study entry.”

Source: [ORIC Pharmaceuticals dose exploration completion release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-completion-of-dose-exploration-portion-of-oric-944-phase-1b-clinical-trial-and-continues-to-demonstrate-potential-best-in-class-efficacy-and-safety/)

<a id="topic-3.1.2.7.1-5"></a>

###### Darolutamide dose optimization: participants analyzed at the January and March 2026 cutoffs

> “As of March 6, 2026, radiographic progression-free survival (rPFS) was assessed in 18 efficacy-evaluable patients. PSA responses were assessed in a subset of 15 patients with at least one post-baseline assessment as of the January 16, 2026 clinical cutoff. ctDNA molecular response was evaluated in 14 patients with detectable ctDNA at baseline.”
> “In a broader dataset of post-ARPI (androgen receptor pathway inhibitor) patients (n=72, inclusive of the post-abiraterone patients), the safety and tolerability profile was consistent with the post-abiraterone cohort.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-3.1.2.7.1-6"></a>

###### Darolutamide dose optimization, post-androgen receptor pathway inhibitor safety set: participants at the January 2026 cutoff

> “Rinzimetostat 600 mg QD + Darolutamide (n=35) Rinzimetostat 400 mg QD + Darolutamide (n=37)”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.7.1-7"></a>

###### Food-effect cohort: participants at the March 2026 cutoff

> “Furthermore, as of March 6, 2026, early efficacy and safety are consistent with fasted results, with two confirmed PSA50 responses and one confirmed PSA90 response in the first five patients dosed”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Single-agent and apalutamide combination cohorts: adverse event attribution

> “Treatment related adverse events (TRAEs) include any adverse event attributed to either ORIC-944 or apalutamide.”

Source: [ORIC Pharmaceuticals January presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525005028/d908680dex991.htm)

<a id="topic-3.1.2.7.2-2"></a>

###### Combination dose exploration: PSA, circulating tumor DNA, and safety sets at the September 2025 cutoff

> “Excludes three patients previously treated with lutetium 177, one of which achieved a PSA50 response.”
> “From the 20-patient data-cut, ctDNA data are included for 17 patients, with 2 patients lacking samples for ctDNA assessment and 1 patient without evidence of ctDNA at baseline.”
> “Germline, predicted clonal hematopoiesis, and synonymous somatic variants were excluded from ctDNA analysis.”
> “Includes all treatment-emergent adverse events (TEAEs) attributed to ORIC-944 plus apalutamide or ORIC-944 plus darolutamide.”

Source: [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm)

<a id="topic-3.1.2.7.2-3"></a>

###### Darolutamide dose optimization, 400 mg: PSA and circulating tumor DNA sets at the March 2026 update

> “Excludes three patients without post-baseline PSA assessments.”
> “Excludes one patient without evidence of ctDNA at baseline, and three patients without ctDNA data available. Likely germline variants and clonal hematopoiesis variants were excluded from ctDNA analysis.”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.7.2-4"></a>

###### Darolutamide dose optimization, post-androgen receptor pathway inhibitor safety set: composition

> “Includes post-abiraterone patients.”
> “Post-ARPI includes post-abiraterone patients.”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Apalutamide combination dose escalation: disposition at the December 2024 cutoff

> “The first two dose levels cleared without dose limiting toxicities or treatment discontinuations related to safety. Dose escalation is ongoing.”

Source: [ORIC Pharmaceuticals early combination data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-provides-early-phase-1b-combination-data-for-oric-944-operational-highlights-for-2024-and-anticipated-upcoming-milestones/)

<a id="topic-3.1.2.8.1-2"></a>

###### Combination dose exploration: treatment status at the May 2025 cutoff

> “The majority of patients are still ongoing with multiple patients approaching one year or more on therapy.”

Source: [ORIC Pharmaceuticals preliminary phase 1b data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-potentially-best-in-class-preliminary-efficacy-and-safety-data-from-ongoing-phase-1b-trial-of-oric-944-in-combination-with-ar-inhibitors-for-the-treatment-of-patie/)

<a id="topic-3.1.2.8.1-3"></a>

###### Combination dose exploration: dose holds and discontinuation at the September 2025 cutoff

> “One additional PSA50 response pending confirmation (denoted by p50); patient had dose hold due to ankle fracture.”
> “One patient came off drug due to TRAE of G1 diarrhea / G2 nausea and lost opportunity to confirm PSA50 response.”

Source: [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm)

<a id="topic-3.1.2.8.1-4"></a>

###### Darolutamide dose optimization, 400 mg: treatment status and discontinuation at the January and March 2026 cutoffs

> “Dose modifications were rare (one interruption and one discontinuation), with no dose reductions required.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

> “Many patients remain on treatment with few reports of radiographic progression”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Combination dose exploration: demographics and baseline characteristics at the September 2025 cutoff

| Characteristic | Rinzimetostat plus apalutamide or darolutamide (N=20) |
| --- | --- |
| Age, median (range), years | “71 (48-85)” |
| Race, White / Black or African American / Asian, % | “70 / 25 / 5” |
| ECOG performance status 0 / 1, n (%) | “12 (60) / 8 (40)” |
| Gleason score <8 / ≥8, n (%) | “4 (20) / 15 (75)” |
| Prior lines of therapy, median (range) | “3 (2-5)” |
| Prior abiraterone, n (%) | “20 (100)” |
| Prior docetaxel, n (%) | “7 (35)” |
| Prior immune therapy, n (%) | “7 (35)” |
| Prior PARP inhibitor, n (%) | “2 (10)” |
| Prior radium 223, n (%) | “2 (10)” |
| Prior other therapy, n (%) | “6 (30)” |
| Bone metastases, n (%) | “17 (85)” |
| Lymph node metastases, n (%) | “8 (40)” |
| Visceral metastases, n (%) | “3 (15)” |

Source: [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm)

> “Patients previously treated with a median of three prior therapies, including abiraterone and a variety of other approved and investigational treatment regimens”
> “Gleason score was missing for one (5%) patient. Immune therapy includes nivolumab, pembrolizumab, atezolizumab, and sipuleucel-T. Other therapies include abemaciclib, cabozantinib, CYP11A, and KLK2 CAR-T.”

Source: [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm)

<a id="topic-3.1.2.8.2-2"></a>

###### Darolutamide dose optimization, 400 mg and 600 mg post-abiraterone cohorts: demographics and baseline characteristics at the January 2026 cutoff

| Characteristic | Rinzimetostat 400 mg QD plus darolutamide (n=18) | Rinzimetostat 600 mg QD plus darolutamide (n=15) |
| --- | --- | --- |
| Age, median (range), years | “67 (51, 85)” | “77 (58, 91)” |
| Race, White / Black / Asian, % | “56 / 33 / 6” | “67 / 27 / 0” |
| ECOG performance status 0 / 1, % | “56 / 44” | “53 / 47” |
| Gleason score <8 / ≥8 / unknown, % | “6 / 67 / 28” | “33 / 40 / 27” |
| Baseline PSA, median, ng/mL | “26” | “12” |
| Prior lines of therapy, median (range) | “2 (1-4)” | “2 (1-4)” |
| Prior abiraterone, n (%) | “18 (100)” | “15 (100)” |
| Prior docetaxel, n (%) | “7 (39)” | “2 (13)” |
| Prior immune therapy, n (%) | “3 (17)” | “2 (13)” |
| Prior PARP inhibitor, n (%) | “1 (6)” | “3 (20)” |
| Prior radium 223, n (%) | “3 (17)” | “0” |
| Prior other therapy, n (%) | “1 (6)” | “0” |
| Bone metastases, n (%) | “15 (83)” | “12 (80)” |
| Lymph node metastases, n (%) | “9 (50)” | “4 (27)” |
| Lung metastases, n (%) | “1 (6)” | “3 (20)” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “Patients previously treated with a median of two prior therapies, including abiraterone, docetaxel, and a variety of other approved and investigational treatment regimens”
> “Immune therapy includes nivolumab, pembrolizumab, atezolizumab, and sipuleucel-T. Other therapies includes cabozantinib. Number of prior lines of therapy excludes background androgen deprivation therapy or first-generation AR inhibitors.”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Single-agent dose escalation: pharmacokinetics and target engagement at the December 2023 cutoff

> “Potential best-in-class drug properties, including clinical half-life consistent with preclinical prediction of >10 hours, which is superior to other PRC2 inhibitors and supports QD dosing”
> “Robust target engagement with maximal decrease (≥75%) in H3K27me3 in monocytes from peripheral blood samples at doses as low as 200 mg QD, with low inter-patient variability”

Source: [ORIC Pharmaceuticals initial phase 1b data release (2024)](https://oricpharma.com/news/oric-pharmaceuticals-provides-initial-phase-1b-data-for-oric-944-operational-highlights-for-2023-and-anticipated-upcoming-milestones/)

> “Exposures at ≥600 mg QD exceed target Cmin that provides 90% TGI in preclinical in vivo prostate cancer models”

Source: [ORIC Pharmaceuticals January presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525005028/d908680dex991.htm)

> “As of December 10, 2023, these data demonstrated potential best-in-class drug properties, including an approximate 20-hour clinical half-life and no signs of cytochrome P450 autoinduction that is seen with first-generation PRC2 inhibitors.”

Source: [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

<a id="topic-3.1.2.8.3-2"></a>

###### Apalutamide combination dose escalation, 600 mg and 800 mg: PSA response at the December 2024 cutoff

> “Deep prostate-specific antigen (PSA) decreases across both the 600 mg and 800 mg dose cohorts; 3 of 6 patients achieved confirmed PSA50 responses, of which 2 achieved confirmed PSA90 responses. All the PSA responses were maintained at ≥12 weeks, including a durable confirmed PSA90 response ongoing at 38 weeks.”
> “Preliminary clinical activity seen to date is consistent with the apalutamide combination cohort.”

Source: [ORIC Pharmaceuticals early combination data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-provides-early-phase-1b-combination-data-for-oric-944-operational-highlights-for-2024-and-anticipated-upcoming-milestones/)

<a id="topic-3.1.2.8.3-3"></a>

###### Combination dose exploration, 400 mg to 800 mg: PSA response at the May 2025 cutoff

> “PSA response data are as of May 9, 2025.”
> “59% of patients (10/17) achieved a PSA50 response and nearly all patients with a PSA50 response were confirmed one month later, for a confirmed PSA50 response rate of 47% (8/17), which does not include one additional PSA response pending confirmation. 24% of patients (4/17) achieved a PSA90 response, all of which were subsequently confirmed.”
> “PSA responses were observed across all ORIC-944 dose levels and were also observed at comparable rates in combination with apalutamide or with darolutamide.”

Source: [ORIC Pharmaceuticals preliminary phase 1b data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-potentially-best-in-class-preliminary-efficacy-and-safety-data-from-ongoing-phase-1b-trial-of-oric-944-in-combination-with-ar-inhibitors-for-the-treatment-of-patie/)

<a id="topic-3.1.2.8.3-4"></a>

###### Combination dose exploration, 400 mg to 1,200 mg: PSA response at the September 2025 cutoff

| Response | Unconfirmed | Confirmed |
| --- | --- | --- |
| PSA50 | “11/20 (55%)” | “8/20 (40%)” |
| PSA90 | “4/20 (20%)” | “4/20 (20%)” |

Source: [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm)

> “PSA90 response ongoing >1 year”
> “One patient developed bone progression and PSA50 was not confirmed.”

Source: [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm)

<a id="topic-3.1.2.8.3-5"></a>

###### Combination dose exploration, 400 mg to 1,200 mg: circulating tumor DNA response and clearance at the September 2025 cutoff

> “In the Phase 1b trial, 88% of patients had detectable ctDNA at baseline”
> “Rapid and deep ctDNA responses across a breadth of AR mutations and other gene alterations, with 76% of patients (13/17) achieving >50% ctDNA reduction.”
> “59% of patients (10/17) achieved ctDNA clearance, which is greater than clearance rates observed in precedent trials with standard of care agents in comparable mCRPC patient populations.”

Source: [ORIC Pharmaceuticals dose exploration completion release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-completion-of-dose-exploration-portion-of-oric-944-phase-1b-clinical-trial-and-continues-to-demonstrate-potential-best-in-class-efficacy-and-safety/)

| ctDNA status, baseline to on-treatment | Quoted value |
| --- | --- |
| Detected to not detected | “59% (10/17)” |
| Detected to detected | “29% (5/17)” |
| Not detected to not detected | “12% (2/17)” |
| Not detected to detected | “0% (0/17)” |

Source: [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm)

<a id="topic-3.1.2.8.3-6"></a>

###### Darolutamide dose optimization, 400 mg: landmark radiographic progression-free survival at the March 2026 cutoff

> “With a median follow up of 4.9 months, landmark rPFS rates of 93%, 84%, and 84% at 3, 4, and 5 months, respectively”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

| Landmark | Radiographic progression-free survival (median follow-up 4.9 months) |
| --- | --- |
| Month 3 | “3-Month 93%” |
| Month 4 | “4-Month 84%” |
| Month 5 | “5-Month 84%” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.8.3-7"></a>

###### Darolutamide dose optimization, 400 mg: PSA response at the January and March 2026 cutoffs

> “47% of patients (7/15) achieved a PSA50 response, with 33% (5/15) confirmed.”
> “PSA responses were assessed in a subset of 15 patients with at least one post-baseline assessment as of the January 16, 2026 clinical cutoff.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

| Response | Unconfirmed | Confirmed |
| --- | --- | --- |
| PSA50 | “7/15 (47%)” | “5/15 (33%)” |
| PSA90 | “2/15 (13%)” | “1/15 (7%)” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “Broad and deep PSA responses observed for 400 mg QD rinzimetostat in combination with darolutamide Source: ORIC data on file as of March 6, 2026.”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.8.3-8"></a>

###### Darolutamide dose optimization, 400 mg: circulating tumor DNA molecular response at the March 2026 cutoff

| Response | Quoted value |
| --- | --- |
| MR50 | “10/14 (71%)” |
| MR90 | “4/14 (29%)” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “ctDNA molecular responses across a breadth of genotypes including AR mutations, AR amplified, AR wildtype”
> “High molecular response rate observed in post-abiraterone patients treated with 400 mg QD rinzimetostat Source: ORIC data on file as of March 11, 2026.”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.8.3-9"></a>

###### Darolutamide dose optimization, 600 mg: efficacy relative to 400 mg in the exposure-response analysis at the January 2026 cutoff

> “The analysis demonstrated that 400 mg and 600 mg once daily provided comparable efficacy.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-3.1.2.8.3-10"></a>

###### Single-agent and darolutamide combination cohorts: pharmacokinetics and target engagement at the March 2026 update

> “Rinzimetostat pharmacokinetic and pharmacodynamic data were highly consistent as a single agent and in combination with darolutamide, and supportive of dose optimization of 400 mg and 600 mg QD”
> “half-life of ~20h supports QD dosing”
> “n=3 or 4 patients per group”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.8.3-11"></a>

###### Post-androgen receptor inhibitor cohort, 400 mg: landmark radiographic progression-free survival at the March 2026 cutoff

> “Early data from rinzimetostat in 19 patients with mCRPC previously treated with AR inhibitors demonstrated compelling landmark rPFS rates of 93%, 85%, and 85% at 3, 4, and 5 months, respectively, with a median follow-up of 4.8 months.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

> “Source: ORIC data on file as of March 6, 2026 from dose optimization trial.”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.8.3-12"></a>

###### Food-effect cohort, 400 mg fed: pharmacokinetics and PSA response at the March 2026 cutoff

> “Thus far, there does not appear to be a significant food effect, consistent with previous single agent studies. Furthermore, as of March 6, 2026, early efficacy and safety are consistent with fasted results, with two confirmed PSA50 responses and one confirmed PSA90 response in the first five patients dosed”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Single-agent dose escalation: safety at the December 2023 cutoff

> “Favorable safety with only grade 1 and 2 treatment-related adverse events at dose levels corresponding with strong target engagement.”

Source: [ORIC Pharmaceuticals initial phase 1b data release (2024)](https://oricpharma.com/news/oric-pharmaceuticals-provides-initial-phase-1b-data-for-oric-944-operational-highlights-for-2023-and-anticipated-upcoming-milestones/)

<a id="topic-3.1.2.8.5-2"></a>

###### Single-agent dose escalation: treatment-related adverse events in at least 10% of participants at the December 2024 cutoff

| Preferred term | 900 mg (N=6), all grade, n (%) | 900 mg (N=6), grade 3, n (%) | Total (N=25), all grade, n (%) | Total (N=25), grade 3, n (%) |
| --- | --- | --- | --- | --- |
| Diarrhea | “2 (33)” | “–” | “10 (40)” | “–” |
| Fatigue | “3 (50)” | “–” | “8 (32)” | “–” |
| Decreased appetite | “1 (17)” | “–” | “8 (32)” | “–” |
| Nausea | “3 (50)” | “–” | “7 (28)” | “–” |
| Anemia | “2 (33)” | “2 (33)” | “5 (20)” | “3 (12)” |
| Platelet count decreased | “3 (50)” | “2 (33)” | “5 (20)” | “2 (8)” |
| White blood cell count decreased | “2 (33)” | “1 (17)” | “3 (12)” | “1 (4)” |
| Blood creatinine increased | “1 (17)” | “–” | “3 (12)” | “–” |
| Dizziness | “1 (17)” | “–” | “3 (12)” | “–” |
| Vomiting | “1 (17)” | “–” | “3 (12)” | “–” |

Source: [ORIC Pharmaceuticals January presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525005028/d908680dex991.htm)

> “All data as of December 10, 2024. Severity grade according to NCI CTCAE v5.0. No Grade 4 or Grade 5 events reported.”

Source: [ORIC Pharmaceuticals January presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525005028/d908680dex991.htm)

<a id="topic-3.1.2.8.5-3"></a>

###### Apalutamide combination dose escalation, 600 mg and 800 mg: safety at the December 2024 cutoff

> “Well-tolerated safety, with primarily Grade 1 and Grade 2 treatment related adverse events (TRAE), consistent with PRC2 and androgen receptor (AR) inhibition, and one Grade 3 TRAE of fatigue (patient remains on treatment without dose modification).”

Source: [ORIC Pharmaceuticals early combination data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-provides-early-phase-1b-combination-data-for-oric-944-operational-highlights-for-2024-and-anticipated-upcoming-milestones/)

<a id="topic-3.1.2.8.5-4"></a>

###### Combination dose exploration, 400 mg to 800 mg: safety at the April 2025 cutoff

> “As of April 22, 2025, diarrhea was the most common treatment-related AE, occurring in 53% of patients (9/17) across all dose levels with only one patient experiencing a Grade 3 event. There were no Grade 4 or Grade 5 treatment-related AEs attributed to ORIC-944 with apalutamide or with darolutamide.”

Source: [ORIC Pharmaceuticals preliminary phase 1b data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-potentially-best-in-class-preliminary-efficacy-and-safety-data-from-ongoing-phase-1b-trial-of-oric-944-in-combination-with-ar-inhibitors-for-the-treatment-of-patie/)

<a id="topic-3.1.2.8.5-5"></a>

###### Combination dose exploration, 400 mg to 1,200 mg: treatment-emergent adverse events attributed to study treatment at the September 2025 cutoff

| Preferred term | 400 mg (n=3), grade 1-2 | 400 mg, grade 3 | 600 mg (n=9), grade 1-2 | 600 mg, grade 3 | 800 mg (n=5), grade 1-2 | 800 mg, grade 3 | 1,200 mg (n=3), grade 1-2 | 1,200 mg, grade 3 | Total (N=20), grade 1-2 | Total, grade 3 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Diarrhea | “1 (33%)” | “–” | “3 (33%)” | “1 (11%)” | “4 (80%)” | “–” | “3 (100%)” | “–” | “11 (55%)” | “1 (5%)” |
| Fatigue | “1 (33%)” | “–” | “4 (44%)” | “–” | “3 (60%)” | “–” | “1 (33%)” | “–” | “9 (45%)” | “–” |
| Nausea | “1 (33%)” | “–” | “3 (33%)” | “–” | “2 (40%)” | “–” | “1 (33%)” | “–” | “7 (35%)” | “–” |
| Dysgeusia | “1 (33%)” | “–” | “2 (22%)” | “–” | “1 (20%)” | “–” | “1 (33%)” | “–” | “5 (25%)” | “–” |
| Vomiting | “–” | “–” | “3 (33%)” | “–” | “1 (20%)” | “–” | “–” | “–” | “4 (20%)” | “–” |
| Hypothyroidism | “–” | “–” | “2 (22%)” | “–” | “1 (20%)” | “–” | “1 (33%)” | “–” | “4 (20%)” | “–” |
| Constipation | “–” | “–” | “2 (22%)” | “–” | “1 (20%)” | “–” | “–” | “–” | “3 (15%)” | “–” |
| Blood creatinine increased | “1 (33%)” | “–” | “–” | “–” | “1 (20%)” | “–” | “1 (33%)” | “–” | “3 (15%)” | “–” |

Source: [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm)

> “No Grade 4 or Grade 5 TEAEs attributed to ORIC-944 with apalutamide or with darolutamide”
> “The occurrence of hypothyroidism is consistent with the known safety profile of apalutamide.”

Source: [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm)

<a id="topic-3.1.2.8.5-6"></a>

###### Darolutamide dose optimization, 400 mg post-abiraterone cohort: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff

| Preferred term | Grade 1, n (%) | Grade 2, n (%) | Grade 3, n (%) | All grade, n (%) |
| --- | --- | --- | --- | --- |
| Fatigue | “3 (17)” | “4 (22)” | “–” | “7 (39)” |
| Diarrhea | “3 (17)” | “1 (6)” | “–” | “4 (22)” |
| Nausea | “4 (22)” | “–” | “–” | “4 (22)” |
| Blood creatinine increased | “2 (11)” | “1 (6)” | “–” | “3 (17)” |
| Decreased appetite | “1 (6)” | “1 (6)” | “–” | “2 (11)” |
| Anemia | “1 (6)” | “1 (6)” | “–” | “2 (11)” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “The most common TRAEs were fatigue (39%; 17% Grade 1 and 22% Grade 2), diarrhea (22%; 17% Grade 1 and 6% Grade 2) and nausea (22%; all Grade 1). A single Grade 3 TRAE was observed, and no Grade 4 or 5 AEs were attributed to rinzimetostat or darolutamide.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-3.1.2.8.5-7"></a>

###### Darolutamide dose optimization, 600 mg post-abiraterone cohort: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff

| Preferred term | Grade 1, n (%) | Grade 2, n (%) | Grade 3, n (%) | All grade, n (%) |
| --- | --- | --- | --- | --- |
| Fatigue | “4 (27)” | “2 (13)” | “–” | “6 (40)” |
| Diarrhea | “3 (20)” | “2 (13)” | “–” | “5 (33)” |
| Nausea | “2 (13)” | “2 (13)” | “–” | “4 (27)” |
| Blood creatinine increased | “2 (13)” | “–” | “–” | “2 (13)” |
| Decreased appetite | “–” | “1 (7)” | “–” | “1 (7)” |
| Anemia | “2 (13)” | “–” | “–” | “2 (13)” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “The 600 mg dose of rinzimetostat in combination with darolutamide was associated with a modestly higher rate of adverse events and dose modifications.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-3.1.2.8.5-8"></a>

###### Darolutamide dose optimization, 400 mg post-androgen receptor pathway inhibitor safety set: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff

| Preferred term | Grade 1, n (%) | Grade 2, n (%) | Grade 3, n (%) | All grade, n (%) |
| --- | --- | --- | --- | --- |
| Fatigue | “4 (11)” | “6 (16)” | “–” | “10 (27)” |
| Diarrhea | “6 (16)” | “1 (3)” | “–” | “7 (19)” |
| Nausea | “7 (19)” | “–” | “–” | “7 (19)” |
| Blood creatinine increased | “3 (8)” | “2 (5)” | “1 (3)” | “6 (16)” |
| Decreased appetite | “1 (3)” | “4 (11)” | “–” | “5 (14)” |
| Anemia | “3 (8)” | “1 (3)” | “–” | “4 (11)” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “8% Grade 3”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.8.5-9"></a>

###### Darolutamide dose optimization, 600 mg post-androgen receptor pathway inhibitor safety set: treatment-emergent adverse events attributed to study treatment at the January 2026 cutoff

| Preferred term | Grade 1, n (%) | Grade 2, n (%) | Grade 3, n (%) | All grade, n (%) |
| --- | --- | --- | --- | --- |
| Fatigue | “5 (14)” | “3 (9)” | “–” | “8 (23)” |
| Diarrhea | “8 (23)” | “5 (14)” | “–” | “13 (37)” |
| Nausea | “5 (14)” | “3 (9)” | “–” | “8 (23)” |
| Blood creatinine increased | “5 (14)” | “3 (9)” | “–” | “8 (23)” |
| Decreased appetite | “4 (11)” | “1 (3)” | “–” | “5 (14)” |
| Anemia | “2 (6)” | “3 (9)” | “1 (3)” | “6 (17)” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “11% Grade 3”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.8.5-10"></a>

###### Darolutamide dose optimization, post-androgen receptor pathway inhibitor safety set (400 mg and 600 mg): grade 4 events at the January 2026 cutoff

> “One Grade 4 of acute kidney injury”
> “In a broader post-ARPI safety dataset, rinzimetostat in combination with darolutamide is generally well-tolerated, with almost all TRAEs Grade 1 or 2 in severity”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.8.5-11"></a>

###### Darolutamide dose optimization, post-abiraterone cohorts (400 mg and 600 mg): dose modifications and discontinuations at the January 2026 cutoff

| Measure | Rinzimetostat 400 mg QD plus darolutamide (n=18) | Rinzimetostat 600 mg QD plus darolutamide (n=15) |
| --- | --- | --- |
| Dose interruptions | “6%” | “13%” |
| Dose reductions | “None” | “7%” |
| Treatment discontinuations | “6%” | “13%” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.8.5-12"></a>

###### Darolutamide dose optimization, post-androgen receptor pathway inhibitor safety set (400 mg and 600 mg): dose modifications and discontinuations at the January 2026 cutoff

| Measure | Rinzimetostat 400 mg QD plus darolutamide (n=37) | Rinzimetostat 600 mg QD plus darolutamide (n=35) |
| --- | --- | --- |
| Dose interruptions | “11%” | “17%” |
| Dose reductions | “3%” | “9%” |
| Treatment discontinuations | “3%” | “11%” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.8.5-13"></a>

###### Darolutamide dose optimization, 400 mg post-abiraterone cohort: grade 3 and serious treatment-related adverse events at the January 2026 cutoff

| Measure | Rinzimetostat 400 mg QD plus darolutamide (n=18) |
| --- | --- |
| Grade ≥3 treatment-related adverse events | “6%” |
| Serious treatment-related adverse events | “None” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.8.5-14"></a>

###### Food-effect cohort, 400 mg fed: safety at the March 2026 cutoff

> “all TRAEs reported being Grade 1 with a single Grade 2 TRAE”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary: design and data limitations

- ORIC-944-01 is a first-in-human, open-label, multicenter phase 1/1b study with an interval 3+3 dose escalation design. Every cohort received rinzimetostat, alone or with an ARPI, and the study has no control arm. The primary endpoints of combination dose optimization are safety and the RP3D; rPFS, objective response rate, and duration of response are key secondary endpoints, and PSA and ctDNA are exploratory endpoints. The registry lists an estimated enrollment of 275 and an estimated primary completion in 2027-06.
- Cohorts are small: 25 participants in single-agent dose escalation, 6 in the first apalutamide combination cohorts, 17 and then 20 in combination dose exploration, 18 at 400 mg and 15 at 600 mg in the post-abiraterone darolutamide dose-optimization cohorts, 19 in the post-androgen receptor inhibitor cohort, and 5 in the first food-effect report. The dose-exploration results pool participants who received apalutamide or darolutamide at 400 mg to 1,200 mg, and a footnote excludes three participants previously treated with lutetium 177, one of whom achieved a PSA50 response.
- Follow-up is short: a median of 4.9 months in the 400 mg post-abiraterone cohort and 4.8 months in the post-androgen receptor inhibitor cohort. rPFS is reported as landmark rates; ORIC states that “Radiographic Progression-Free Survival Data Are Immature” and lists median rPFS as “Not mature”.
- Endpoints of the 400 mg cohort come from different cutoffs and subsets: rPFS as of March 6, 2026 in 18 participants; PSA response at the January 16, 2026 clinical cutoff in 15 participants, excluding three without post-baseline PSA assessments; and ctDNA response in 14 participants (data on file as of March 11, 2026), excluding one without ctDNA at baseline and three without ctDNA data. Unconfirmed PSA responses are reported together with confirmed responses.
- Baseline characteristics differed between the 400 mg and 600 mg post-abiraterone cohorts: median age 67 and 77 years, prior docetaxel 39% and 13%, and median baseline PSA 26 and 12 ng/mL. The exposure-response analysis used to select the RP3D pooled 113 participants from single-agent and combination cohorts.
- All results are company-reported in press releases, investor presentations, and SEC filings. ORIC states that outcomes “may materially change as patient enrollment continues or more patient data become available”, that it may report unconfirmed responses and “interim analyses of only certain endpoints rather than all endpoints”, and that early clinical results “may not be predictive” of later-stage trials. ORIC’s comparisons with mevrometostat use competitor rPFS percentages “estimated from published data” and are labeled cross-trial.

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm); [ORIC Pharmaceuticals January presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525005028/d908680dex991.htm); [ORIC Pharmaceuticals early combination data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-provides-early-phase-1b-combination-data-for-oric-944-operational-highlights-for-2024-and-anticipated-upcoming-milestones/); [ORIC Pharmaceuticals preliminary phase 1b data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-potentially-best-in-class-preliminary-efficacy-and-safety-data-from-ongoing-phase-1b-trial-of-oric-944-in-combination-with-ar-inhibitors-for-the-treatment-of-patie/); [ORIC Pharmaceuticals dose exploration completion release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-completion-of-dose-exploration-portion-of-oric-944-phase-1b-clinical-trial-and-continues-to-demonstrate-potential-best-in-class-efficacy-and-safety/); [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm); [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/); [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

<a id="topic-3.1.2.9-2"></a>

###### Immature radiographic progression-free survival and early landmark analyses

> “Radiographic Progression-Free Survival Data Are Immature, but Early Landmark Analyses Are Promising”
> “Preliminary rinzimetostat rPFS landmark analysis, albeit early”
> “Preliminary data in second mCRPC population, albeit early, are promising”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.9-3"></a>

###### Cross-trial comparisons with estimated competitor values

> “Note: Competitor rPFS percentages estimated from published data. PSA50 represents confirmed responses. Cross-trial comparison in previously treated mCRPC patients shown.”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-3.1.2.9-4"></a>

###### Outcomes may change as enrollment continues

> “clinical outcomes from combination studies with rinzimetostat, which may materially change as patient enrollment continues or more patient data become available”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-3.1.2.9-5"></a>

###### Interim and preliminary data subject to change and selective disclosure

> “Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.”
> “For example, we may report tumor responses in certain patients that are unconfirmed at the time and which do not ultimately result in confirmed responses to treatment after follow-up evaluations.”
> “In addition, we may report interim analyses of only certain endpoints rather than all endpoints.”
> “The results from preclinical testing or early clinical trials of a product candidate may not be predictive of the results that will be obtained in later stage clinical trials of the product candidate.”

Source: [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
